	2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	875	1,081	1,133	1,202	1,333	698	815	1,180	1,104	1,235	1,270	1,343	1,785	2,111	2,202
Cost of Operating Revenue	387	482	485	540	553	354	471	611	564	555	610	787	967	1,096	1,252
Gross Profit	489	598	648	662	779	344	343	569	540	681	660	556	818	1,015	950
Gross Margin	55.8	55.4	57.2	55.1	58.5	49.3	42.1	48.2	48.9	55.1	52.0	41.4	45.8	48.1	43.1
Total Operating Expenses	788	945	1,001	1,142	1,208	782	993	1,316	1,234	1,228	1,281	1,499	1,821	1,971	2,143
Operating Profit	88	136	132	60	125	-84	-178	-136	-130	7	-11	-156	-36	140	59
Operating Margin	10.0	12.6	11.7	5.0	9.4	-12.0	-21.9	-11.5	-11.8	0.6	-0.9	-11.6	-2.0	6.6	2.7
Financing Income/(Expense) - Net	2	2	12	9	6	-1	38	61	55	28	38	6	0	3	19
Profit before Taxes	94	146	171	77	137	-83	-130	-60	-48	51	22	-176	-85	155	292
Income Taxes	23	33	43	2	29	-12	3	-34	12	17	-11	26	9	17	40
Profit after Tax	71	113	169	75	108	109	2,545	-24	-60	34	33	-202	-94	138	253
PAT Margin	8.1	10.5	14.9	6.3	8.1	15.6	312.4	-2.0	-5.5	2.8	2.6	-15.1	-5.3	6.5	11.5
EPS - Basic - ex Extraordinary Items	7.89	12.52	14.15	8.31	11.90	-7.78	-14.68	-3.63	-8.55	4.88	4.70	-28.72	-13.32	19.53	35.91
EPS - Diluted - ex Extraordinary Items	7.86	12.48	14.10	8.29	11.88	-7.78	-14.68	-3.63	-8.55	4.88	4.68	-28.72	-13.32	19.47	35.85
EBIT	88	136	132	60	125	-84	-178	-136	-130	7	-11	-156	-36	140	59
EBITDA	118	174	178	101	164	-41	-128	-69	-49	92	80	-42	87	265	184
EBITDA Margin	13.5	16.1	15.7	8.4	12.3	-5.8	-15.7	-5.8	-4.5	7.4	6.3	-3.1	4.9	12.5	8.4

Balance Sheet

Abridged

Understanding Balance Sheet

Unichem Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	439	478	581	564	598	748	2,336	2,038	1,686	1,377	1,645	1,588	1,743	2,029	2,197
Long-Term Investments	0	6	0	46	26	12	9	129	133	158	3	0	6	8	9
Property Plant & Equipment - Net	505	567	507	536	637	734	811	897	1,195	1,446	1,482	1,403	1,317	1,310	1,304
Total Non-Current Assets	549	584	564	604	686	778	857	1,111	1,458	1,748	1,674	1,605	1,532	1,540	1,540
Total Assets	987	1,073	1,145	1,169	1,284	1,527	3,194	3,150	3,145	3,126	3,319	3,193	3,275	3,569	3,737
Total Current Liabilities	233	251	230	190	243	393	464	503	567	506	552	640	738	992	886
Long Term Debt	20	21	25	20	23	0	0	-	18	14	104	75	62	86	65
Total Non-Current Liabilities	93	94	98	89	86	70	50	27	47	63	148	118	99	127	134
Total Liabilities	326	345	328	279	329	463	514	530	613	569	700	758	837	1,119	1,020
Total Shareholders' Equity	661	727	817	889	954	1,064	2,680	2,620	2,531	2,557	2,618	2,435	2,438	2,451	2,717
Total Equity	661	727	817	889	954	1,064	2,680	2,620	2,531	2,557	2,618	2,435	2,438	2,451	2,717
Total Liabilities & Equity	987	1,073	1,145	1,169	1,284	1,527	3,194	3,150	3,145	3,126	3,319	3,193	3,275	3,569	3,737

Cash Flow

Abridged

Understanding Cash Flow Statement

Unichem Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	C 2022 Mar 31	2023 Mar 31	R 2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	108	155	157	101	150	166	48	-26	5	128	114	-71	84	269	192
Working Capital - Increase/(Decrease)	14	13	-66	-16	-36	-99	-147	-265	54	-70	-354	-29	-92	-294	-208
Net CF from Operating Activities	122	168	90	84	114	67	-99	-291	59	58	-240	-100	-8	-25	-16
Capital Expenditures - Net	111	97	-41	74	140	147	158	192	380	287	127	38	14	135	-160
Net CF from Investing Activities	-103	-119	29	-62	-90	-130	1,627	-332	-82	-103	78	202	50	-243	186
Dividends Paid - Cash - Total	25	27	76	36	43	1	33	42	34	29	28	28	0	0	0
Stock - Issuance/(Retirement) - Net	0	1	1	1	0	0	-886	0	0	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	19	-19	-1	-4	14	62	53	49	-21	-88	225	-37	-84	204	27
Net Cash Flow from Financing Activities	-10	-48	-92	-48	-31	63	-873	7	-55	-117	196	-65	-84	203	27
Free Cash Flow to Equity	29	52	130	6	-12	-18	-205	-434	-343	-317	-142	-175	-105	44	171
Free Operating CF net dividend	-17	43	-90	-30	-91	-83	-292	-528	-361	-258	-395	-173	-30	-163	-139
Free Operating CF	9	70	-14	6	-48	-83	-259	-485	-327	-230	-367	-145	-30	-162	-139

Business Segment Analysis

FY End:

Mar 26

Unichem Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 123.04 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 2,201.85 Cr

Assets

Pharmaceuticals (100.0%)₹ 3,737.44 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 59.05 Cr

Regional Segment Analysis

FY End:

Mar 26

Unichem Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

USA (68.0%)₹ 1,468.53 CrOthers (30.5%)₹ 657.77 CrIndia (1.5%)₹ 33.11 Cr

Historical Segment Analysis

Track how Unichem Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Pharmaceuticals	288	127	44	23	137	123

Frequently Asked Questions

What is the revenue of Unichem Laboratories Ltd.?

The latest trailing twelve month revenue of Unichem Laboratories Ltd. is ₹ 2,201.85 Cr, reflecting a 1-year growth of 4.31% and a 3-year CAGR of 17.91%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Unichem Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Unichem Laboratories Ltd. is ₹ 252.84 Cr. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Unichem Laboratories Ltd.?

The trailing twelve month EBITDA of Unichem Laboratories Ltd. is approximately ₹ 59.05 Cr (based on an operating margin of 2.68%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Unichem Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Unichem Laboratories Ltd. is 35.85. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Unichem Laboratories Ltd.?

The debt-to-equity ratio of Unichem Laboratories Ltd. stands at 0.18. The interest coverage ratio is 1.87x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Unichem Laboratories Ltd.?

The estimated book value per share of Unichem Laboratories Ltd. is 385.97 (derived from a P/B ratio of 1.53 and market price of ₹ 589.05), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Unichem Laboratories Ltd.?

The trailing twelve month operating cash flow of Unichem Laboratories Ltd. is ₹ -15.69 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Unichem Laboratories Ltd. report consolidated or standalone financials?

Unichem Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.